RoystonC, HovorkaR, BoughtonCK. Closed-loop therapy: Recent advancements and potential predictors of glycemic outcomes. Expert Opin Drug Deliv2025;22(6):875–892; doi: 10.1080/17425247.2025.2492363
2.
RakabMS, RatebRM, ElsalakawiBH, et al.Ultra-rapid lispro or fast-acting aspart compared to standard insulin lispro and aspart using closed-loop insulin therapy: A systematic review and meta-analysis of randomized control trials. Front Endocrinol (Lausanne)2025;16:1600157; doi: 10.3389/fendo.2025.1600157
3.
StamatiA, KaragiannisT, TsapasA, et al.Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract2022;193:110144; doi: 10.1016/j.diabres.2022.110144
4.
OktavianP, Kencono WunguCD, MudjanarkoSW, et al.A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab2025;27(5):2658–2669; doi: 10.1111/dom.16268
5.
van BonAC, BlauwH, JansenTJP, et al.Bihormonal fully closed-loop system for the treatment of type 1 diabetes: A real-world multicentre, prospective, single-arm trial in the Netherlands. Lancet Digit Health2024;6(4):e272–e280; doi: 10.1016/S2589-7500(24)00002-5
6.
NefsG, JansenTJP, KlaassenM, et al.User experiences of a bihormonal fully closed-loop system among adults with type 1 diabetes in a real-world setting: A qualitative analysis. Diabetes Technol Ther2026:15209156251383522; doi: 10.1177/15209156251383522
7.
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: An international consensus statement. Lancet Diabetes Endocrinol2023;11(1):42–57; doi: 10.1016/S2213-8587(22)00319-9
